Benztropine (BZT) analogs, a family of high-affinity
dopamine transporter ligands, are molecules that exhibit pharmacological and behavioral characteristics predictive of significant therapeutic potential in
cocaine addiction. Here, we examined in mice the effects of 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane (AHN-1055) on motor activity, conditioned place preference (
CPP) and c-Fos expression in the striatum.
AHN-1055 produced mild attenuation of spontaneous locomotor activity at a low dose (1 mg/kg) and weak stimulation at a higher dose (10 mg/kg). In parallel, the BZT analog significantly increased c-Fos expression in the dorsolateral caudoputamen at the high dose, whereas producing marginal decreases at low and moderate doses (1, 3 mg/kg) in both dorsal and ventral striatum. Interaction assays showed that
cocaine's ability to stimulate locomotor activity was decreased by
AHN-1055 treatment, but not by treatment with
D-amphetamine. Such reduced ability did not result from an increase in stereotyped behavior. Another
dopamine uptake inhibitor,
nomifensine, decreased
cocaine-induced locomotor activity but evoked by itself intense motor stereotypies. Remarkably, the BZT analog dose-dependently blocked
cocaine-induced
CPP without producing
CPP when given alone, and blocked in conditioned mice
cocaine-stimulated early-gene activation in the nucleus accumbens and dorsomedial striatum. These observations provide evidence that
AHN-1055 does not behave as a classical psychomotor stimulant and that some of its properties, including attenuation of
cocaine-induced striatal c-Fos expression, locomotor stimulation, and
CPP, support its candidacy, and that of structurally related molecules, as possible
pharmacotherapies in
cocaine addiction.